Talbot Financial LLC Acquires 54,574 Shares of Novo Nordisk A/S (NYSE:NVO)

Talbot Financial LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 115.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,840 shares of the company's stock after purchasing an additional 54,574 shares during the period. Talbot Financial LLC's holdings in Novo Nordisk A/S were worth $7,072,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NVO. M. Kulyk & Associates LLC grew its stake in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after buying an additional 119 shares during the period. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Tradewinds Capital Management LLC boosted its stake in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after buying an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC lifted its position in shares of Novo Nordisk A/S by 4.2% during the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after buying an additional 126 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Trading Up 1.8%

Shares of NYSE:NVO traded up $1.28 during midday trading on Monday, hitting $72.78. 16,798,369 shares of the stock traded hands, compared to its average volume of 6,840,186. The stock has a market capitalization of $326.59 billion, a PE ratio of 22.12, a P/E/G ratio of 0.90 and a beta of 0.65. The business's 50 day moving average is $65.58 and its two-hundred day moving average is $81.43. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.